Change search
ReferencesLink to record
Permanent link

Direct link
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2(3) by High-Throughput Virtual Screening and Automated Patch Clamp
Show others and affiliations
2012 (English)In: ChemMedChem, ISSN 1860-7179, Vol. 7, no 10, 1775-1783 p.Article in journal (Refereed) Published
Abstract [en]

Two voltage-dependent potassium channels, Kv1.1 (KCNA1) and Kv1.2 (KCNA2), are found to co-localize at the juxtaparanodal region of axons throughout the nervous system and are known to co-assemble in heteromultimeric channels, most likely in the form of the concatemer Kv1.11.2(3). Loss of the myelin sheath, as is observed in multiple sclerosis, uncovers the juxtaparanodal region of nodes of Ranvier in myelinated axons leading to potassium conductance, resulting in loss of nerve conduction. The selective blocking of these Kv channels is therefore a promising approach to restore nerve conduction and function. In the present study, we searched for novel inhibitors of Kv1.11.2(3) by combining a virtual screening protocol and electrophysiological measurements on a concatemer Kv1.11.2(3) stably expressed in Chinese hamster ovary K1 (CHO-K1) cells. The combined use of four popular virtual screening approaches (eHiTS, FlexX, Glide, and Autodock-Vina) led to the identification of several compounds as potential inhibitors of the Kv1.11.2(3) channel. From 89 electrophysiologically evaluated compounds, 14 novel compounds were found to inhibit the current carried by Kv1.11.2(3) channels by more than 80?% at 10 mu M. Accordingly, the IC50 values calculated from concentrationresponse curve titrations ranged from 0.6 to 6 mu M. Two of these compounds exhibited at least 30-fold higher potency in inhibition of Kv1.11.2(3) than they showed in inhibition of a set of cardiac ion channels (hERG, Nav1.5, and Cav1.2), resulting in a profile of selectivity and cardiac safety. The results presented herein provide a promising basis for the development of novel selective ion channel inhibitors, with a dramatically lower demand in terms of experimental time, effort, and cost than a sole high-throughput screening approach of large compound libraries.

Place, publisher, year, edition, pages
2012. Vol. 7, no 10, 1775-1783 p.
Keyword [en]
drug design, hERG, KCNA2, Kv1, 1-1, 2(3), virtual screening
National Category
URN: urn:nbn:se:kth:diva-103761DOI: 10.1002/cmdc.201100600ISI: 000309071400006ScopusID: 2-s2.0-84866772480OAI: diva2:563100
Swedish eā€Science Research CenterEU, FP7, Seventh Framework Programme, HEALTH-F4-2007-201924Science for Life Laboratory - a national resource center for high-throughput molecular bioscience

QC 20121029

Available from: 2012-10-29 Created: 2012-10-19 Last updated: 2013-04-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Lindahl, Erik
By organisation
Theoretical & Computational Biophysics
In the same journal

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 30 hits
ReferencesLink to record
Permanent link

Direct link